OnKure Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure's product candidates aim to treat cancer by targeting malignant cells and circulating lymphocytes, through alteration of the tumor microenvironment such that checkpoint inhibition is optimized, and through delaying kinase inhibitor resistance. OnKure's most advanced programs target Class-1 histone deacetylase (HDAC) enzymes as well as HDAC6.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/02/18 | $7,000,000 | Series A |
Delian Capital | undisclosed |
